RhumbLine Advisers
TELO icon

RhumbLine Advisers’s Telomir Pharmaceuticals TELO Stock Holding History

RhumbLine Advisers’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,732
Closed -$37.9K – 4285
2025
Q1 		$37.9K Buy
11,732
+3,132
+36% +$13.7K ﹤0.01% 3631
2024
Q4 		$35.4K Buy
8,600
+4,424
+106% +$20.8K ﹤0.01% 3723
2024
Q3 		$26.8K Sell
4,176
-886
-18% -$4.32K ﹤0.01% 3781
2024
Q2 		$24.3K Buy
+5,062
New +$31.6K ﹤0.01% 3836

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

RhumbLine Advisers's TELO Position: Q2 2025 in Review

RhumbLine Advisers sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 11,732 shares — an estimated $37.9K sold.

RhumbLine Advisers first reported a position in TELO in Q2 2024 and held it in 4 quarters. The position peaked at $37.9K in Q1 2025. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

  • RhumbLine Advisers reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 11,732 Telomir Pharmaceuticals shares in Q2 2025, an estimated $37.9K.
  • RhumbLine Advisers first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Telomir Pharmaceuticals position peaked at $37.9K in Q1 2025.
  • 43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.